Stock Analysis on Net

Cigna Group (NYSE:CI)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 27, 2025.

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Profitability Ratios (Summary)

Cigna Group, profitability ratios (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Return on Sales
Gross profit margin
Operating profit margin
Net profit margin
Return on Investment
Return on equity (ROE)
Return on assets (ROA)

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


Gross Profit Margin
The gross profit margin demonstrates a declining trend over the observed period. Starting at 14.04% in the first quarter of 2021, it gradually decreased to 12.3% by the first quarter of 2022. Subsequent quarters reflect a continued reduction with minor fluctuations, ultimately falling to 10.15% by the end of 2024. This steady decline indicates increasing cost pressures or pricing challenges impacting the core profitability of the company’s operations.
Operating Profit Margin
The operating profit margin exhibits a generally stable pattern with slight fluctuations. It starts near 4.98% in early 2021 and decreases modestly to around 4.6% by the end of 2021. Following this, there is a mild recovery reaching approximately 4.7% mid-2022, but thereafter, a gradual decline is observed across subsequent quarters, concluding at 3.83% by the end of 2024. Overall, despite some volatility, the operating margin shows a weakening trend, suggesting rising operational expenses or pressures on operational efficiency.
Net Profit Margin
The net profit margin shows notable volatility with an overall downward trajectory. Initially, it is moderately strong at 5.22% in early 2021 but declines sharply to around 3.1% by late 2021. It slightly recovers through 2022 but remains below initial levels. From 2023 onward, the net margin continues to compress, reaching as low as 1.31% by the third quarter of 2024 before a marginal increase to 1.4% by year-end. This pattern signals increased financial pressures after operating costs, including taxes, interest, or other expenses.
Return on Equity (ROE)
The ROE experiences significant fluctuation over the analyzed period. Starting from a relatively high 17.52% in early 2021, it declines sharply to approximately 11.39% by the end of that year. Recovery occurs through 2022, peaking near 15.17% in the first quarter of 2023. However, subsequent quarters depict a marked downtrend, dropping further to a low point of 7.22% in the third quarter of 2024 with a slight rebound to 8.37% by the end of 2024. This indicates variability in shareholder returns tied to net income fluctuations and equity base changes, reflecting the company's decreasing profitability and possibly increased equity levels.
Return on Assets (ROA)
The ROA follows a declining trend with periods of limited recovery. Starting at 5.55% in early 2021, it decreases to 3.46% towards the end of 2021. There is a moderate rebound into mid-2022 reaching about 4.63%, followed by a gradual decline to 2.2% by the close of 2024. The decline in ROA reflects decreasing efficiency in asset utilization to generate profits, consistent with observed trends in net margin and profitability metrics.

Return on Sales


Return on Investment


Gross Profit Margin

Cigna Group, gross profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in millions)
Gross profit
Revenues from external customers
Profitability Ratio
Gross profit margin1
Benchmarks
Gross Profit Margin, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q4 2024 Calculation
Gross profit margin = 100 × (Gross profitQ4 2024 + Gross profitQ3 2024 + Gross profitQ2 2024 + Gross profitQ1 2024) ÷ (Revenues from external customersQ4 2024 + Revenues from external customersQ3 2024 + Revenues from external customersQ2 2024 + Revenues from external customersQ1 2024)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


Revenue Trends
Revenues from external customers demonstrated a consistent upward trend over the entire period. Starting at approximately $40.6 billion in the first quarter of 2021, revenues incrementally increased each quarter, reaching over $65.3 billion by the end of 2024. The growth was particularly notable from 2023 onwards, with revenue rising from around $46.2 billion in the first quarter of 2023 to $65.3 billion in the last quarter of 2024, indicating accelerating sales or business expansion.
Gross Profit Trends
Gross profit exhibited moderate growth over the period analyzed, with fluctuations but an overall upward trajectory. Beginning at $5.3 billion in early 2021, gross profit increased to about $6.2 billion by the end of 2024. This growth, however, was less pronounced relative to revenue growth, with some variability observed from quarter to quarter, including minor declines or plateaus in certain periods such as late 2022 and early 2024.
Gross Profit Margin Analysis
Despite rising revenues and gross profit in absolute terms, the gross profit margin showed a consistent decline throughout the period. The margin decreased from 14.04% in the first quarter of 2021 to 10.15% by the end of 2024. This contraction suggests that the cost of goods sold grew at a faster pace than revenues, or that there were changes in pricing strategies, product mix, or increased input costs, negatively affecting profitability on sales.
Overall Insights
The company's financials reflect robust revenue growth accompanied by incremental gross profit increases. However, the declining gross profit margin raises concerns about cost control or product profitability. The diminishing margin trend may affect overall earnings if not addressed. The data suggests that while top-line growth is strong, maintaining or improving profitability ratios will be critical going forward.

Operating Profit Margin

Cigna Group, operating profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in millions)
Income from operations
Revenues from external customers
Profitability Ratio
Operating profit margin1
Benchmarks
Operating Profit Margin, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q4 2024 Calculation
Operating profit margin = 100 × (Income from operationsQ4 2024 + Income from operationsQ3 2024 + Income from operationsQ2 2024 + Income from operationsQ1 2024) ÷ (Revenues from external customersQ4 2024 + Revenues from external customersQ3 2024 + Revenues from external customersQ2 2024 + Revenues from external customersQ1 2024)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The financial data over the presented periods reveals several notable trends in operating income, revenues, and profit margins.

Income from Operations
The income from operations shows quarter-to-quarter fluctuations but generally exhibits a cyclical pattern. Starting at $1,957 million in the first quarter of 2021, it rose steadily through the initial three quarters, peaking at $2,294 million in the third quarter of 2021 before dropping to $1,537 million in the fourth quarter of that year. In the subsequent year, the income recovered and peaked again in the second quarter of 2022 at $2,381 million. This up-and-down trend continues with peaks generally observed in the second and third quarters, and troughs in the fourth quarters of each year. The latest available data for 2024 shows the income from operations peaking at $2,576 million in the third quarter before decreasing to $2,173 million in the fourth quarter, suggesting persistence of this quarter-dependent variation.
Revenues from External Customers
The revenues demonstrate a consistent upward trajectory across the entire period. From $40,580 million in the first quarter of 2021, revenues increased steadily each quarter, reaching $65,372 million by the first quarter of 2024. This illustrates strong organic growth or possible expansion through other means such as acquisitions. Though seasonal variations are less pronounced than those in operating income, there remain slight quarterly increases with occasional minor slowdowns, but no significant contractions in revenue are observed.
Operating Profit Margin
The operating profit margin shows a gradual declining trend over the analyzed quarters. Initially fluctuating around 4.5% to 5.0% throughout 2021, it begins a slow decrease starting in 2022. By the end of 2024, the margin has declined to 3.83%. This trend indicates that despite increasing revenues, the company is experiencing pressures on operating efficiency or facing higher costs, resulting in a reduced percentage of revenue being converted to operating profit.

Overall, the data depicts a company with steadily increasing revenue but fluctuating operating income, likely influenced by seasonal or cyclical factors. However, the slowly declining operating profit margin raises concerns about rising expenses or decreasing operational leverage. Monitoring cost management and operational efficiency should remain a focus to sustain profitability gains in line with revenue growth.


Net Profit Margin

Cigna Group, net profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in millions)
Shareholders’ net income (loss)
Revenues from external customers
Profitability Ratio
Net profit margin1
Benchmarks
Net Profit Margin, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q4 2024 Calculation
Net profit margin = 100 × (Shareholders’ net income (loss)Q4 2024 + Shareholders’ net income (loss)Q3 2024 + Shareholders’ net income (loss)Q2 2024 + Shareholders’ net income (loss)Q1 2024) ÷ (Revenues from external customersQ4 2024 + Revenues from external customersQ3 2024 + Revenues from external customersQ2 2024 + Revenues from external customersQ1 2024)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The financial data reveals several notable trends in the company’s quarterly performance over the examined periods.

Shareholders’ Net Income (Loss)
The shareholders' net income exhibits fluctuations with periods of both growth and contraction. There was a general increase from early 2021 through the third quarter of 2022, peaking notably at 2,757 million US$ in September 2022. However, this gain was followed by a sharp decline in subsequent quarters, including a significant loss of 277 million US$ in the first quarter of 2024. The latest quarters show a partial recovery with net income rising to 1,424 million US$ by the last quarter of 2024, albeit below the peak observed in late 2022.
Revenues from External Customers
Revenues demonstrate a consistent upward trend throughout the entire timeline. Starting at 40,580 million US$ in the first quarter of 2021, revenues steadily increased each quarter, culminating in 65,372 million US$ by the third quarter of 2024. This continuous revenue growth indicates expanding business operations or enhanced sales performance without any visible periods of decline.
Net Profit Margin
The net profit margin shows a declining trend over the reported quarters. It started at a relatively strong 5.22% in the first quarter of 2021 before moving down to levels near 3.0% during most of 2022 and early 2023. By the end of the period, the margin has reduced further, reaching around 1.3% to 1.4% in late 2024. This decline suggests increasing costs or decreasing profitability relative to sales despite rising revenue levels.

In summary, while the company has succeeded in expanding revenue continuously, profitability metrics indicate challenges. Net income is volatile with a peak followed by sharp decreases and a partial recovery, and profit margins have diminished markedly over the years. These factors highlight the need for a closer examination of cost structures, pricing strategies, or external influences affecting earnings stability and efficiency.


Return on Equity (ROE)

Cigna Group, ROE calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in millions)
Shareholders’ net income (loss)
Shareholders’ equity
Profitability Ratio
ROE1
Benchmarks
ROE, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q4 2024 Calculation
ROE = 100 × (Shareholders’ net income (loss)Q4 2024 + Shareholders’ net income (loss)Q3 2024 + Shareholders’ net income (loss)Q2 2024 + Shareholders’ net income (loss)Q1 2024) ÷ Shareholders’ equity
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The financial performance over the observed quarters demonstrates fluctuations in key metrics related to profitability and equity position. The shareholders’ net income displays a pattern of variability, with certain quarters showing substantial increases while others register declines, reflecting volatility in earnings generation.

Initially, net income shows a general upward trend from March 2021 through September 2022, peaking significantly in September 2022. Thereafter, the figures decline sharply in December 2023 and March 2024, indicating a downturn in profitability for those periods, before partially recovering by December 2024.

Shareholders’ equity exhibits a gradual downward trajectory across the reported periods, suggesting a slow erosion in the equity base. From a high point in early 2021, equity decreases steadily, reaching lower levels by the end of 2024. This decline highlights potential pressures on the company’s capital structure or retained earnings.

The return on equity (ROE) mirrors aspects of the net income variability, with values decreasing notably from the initial higher rates in early 2021 to more moderate levels by the end of 2024. This contraction in ROE indicates reduced efficiency in generating income from equity over time. Notably, ROE values show some minor fluctuations, but the overall trend points towards diminished profitability relative to shareholders’ equity.

Summary of Trends
- Shareholders’ net income experienced significant variability, with noteworthy peaks and troughs indicating volatility in earnings.
- Shareholders’ equity declined gradually but consistently, implying ongoing reductions in the company’s equity base over the periods analyzed.
- Return on equity diminished over the course of the periods, reflecting lower income generation relative to equity invested.
- The interplay between fluctuating net income and declining equity contributed to the observed ROE trends, underscoring challenges in maintaining consistent profitability and capital efficiency.

Return on Assets (ROA)

Cigna Group, ROA calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in millions)
Shareholders’ net income (loss)
Total assets
Profitability Ratio
ROA1
Benchmarks
ROA, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q4 2024 Calculation
ROA = 100 × (Shareholders’ net income (loss)Q4 2024 + Shareholders’ net income (loss)Q3 2024 + Shareholders’ net income (loss)Q2 2024 + Shareholders’ net income (loss)Q1 2024) ÷ Total assets
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of the quarterly financial performance reveals several notable trends and fluctuations across key metrics.

Shareholders' Net Income (Loss)
Over the observed period, the net income demonstrates a pattern of volatility. Initially, net income rises steadily from 1,161 million USD in March 2021 to a peak of 2,757 million USD in September 2022, indicating strong profitability growth through this timeframe. However, a sharp decline follows, falling to 1,169 million USD by December 2022. In 2023, income values show moderate recovery and relative stability with figures ranging roughly between 1,029 million and 1,460 million USD across the quarters. The first quarter of 2024 records a loss of 277 million USD, signaling a significant downturn. This loss is followed by a robust rebound in the subsequent quarters, with net income climbing back to 1,548 million USD in June 2024 and fluctuating thereafter but remaining positive at 1,424 million USD by December 2024.
Total Assets
Total assets remain relatively stable with minor fluctuations. The asset base fluctuates slightly around the 150 billion USD mark throughout the period. Starting at approximately 152 billion USD in early 2021, assets dip somewhat mid-2022 to as low as 144 billion USD, before rebounding progressively toward the end of 2023 and into 2024, reaching a peak of about 157.6 billion USD in September 2024. The trend shows a minor contraction phase followed by gradual asset growth, reflecting manageable asset management and possibly strategic repositioning.
Return on Assets (ROA)
ROA indicates the efficiency of asset utilization to generate earnings and shows a declining trend over time. Initially, ROA drops from a high of 5.55% in March 2021 to approximately 3.46%-4.63% within 2021 and 2022. The metric continues to decline gradually during 2023, moving down from about 4.56% to 3.38%. In 2024, ROA falls further, reaching a low of 1.93% by September, with a slight recovery to 2.2% by the final quarter. This downward trend suggests diminishing profitability relative to the asset base, possibly linked to the increased volatility in net income and other operational challenges.

Overall, the data reflects a period of financial fluctuation characterized by initial profitability growth followed by sharp income volatility and a notable loss in early 2024, before partial recovery. Total assets demonstrate relative steadiness with moderate growth in the latter periods. The declining ROA trend signals reduced efficiency in using assets to generate profits, warranting attention to operational and strategic factors affecting asset returns.